Drug Profile
Ferric derisomaltose - Pharmacosmos
Alternative Names: Diafer; Iron isomaltoside 1000; Iron oligosaccharide; Isofer; Jilazo; Monofar; Monofer; MONOFERRIC; Monoferric; Monover; NS 32Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pharmacosmos
- Developer Cosmopharm; Nippon Shinyaku; Pfizer; Pharmacosmos
- Class Antianaemics; Disaccharides; Ferric compounds
- Mechanism of Action Iron replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Iron deficiency anaemia
- Phase III Metabolic disorders; Postpartum haemorrhage
Most Recent Events
- 17 Mar 2023 Launched for Iron deficiency anaemia in Japan prior to March 2023 (IV)
- 28 Nov 2022 Phase-III clinical trials in Iron deficiency anaemia (In adolescents, In children, In infants, In neonates) in USA (IV) (NCT05179226)
- 28 Oct 2022 University of Glasgow completes a IRONMAN trial for ferric derisomaltose in iron deficiency anaemia (NCT02642562)